[{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Cosibelimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Checkpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Checkpoint Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Checkpoint Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Cosibelimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Checkpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Checkpoint Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Checkpoint Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Public Offering","leadProduct":"Cosibelimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Checkpoint Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"","sponsorNew":"Checkpoint Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Checkpoint Therapeutics \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Cosibelimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Checkpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Checkpoint Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Checkpoint Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"Samsung Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Large molecule","year":"2020","type":"Partnership","leadProduct":"Cosibelimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Checkpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Checkpoint Therapeutics \/ Checkpoint Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Checkpoint Therapeutics \/ Checkpoint Therapeutics"},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Cosibelimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Checkpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Checkpoint Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Checkpoint Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Cosibelimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Checkpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Checkpoint Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Checkpoint Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Cosibelimab","moa":"PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Checkpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Checkpoint Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Checkpoint Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Cosibelimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Checkpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Checkpoint Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Checkpoint Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Public Offering","leadProduct":"Cosibelimab","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Checkpoint Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Checkpoint Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Checkpoint Therapeutics \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Public Offering","leadProduct":"Cosibelimab","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Checkpoint Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Checkpoint Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Checkpoint Therapeutics \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Cosibelimab","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Checkpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Checkpoint Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Checkpoint Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Public Offering","leadProduct":"Cosibelimab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Checkpoint Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"","sponsorNew":"Checkpoint Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"12","companyTruncated":"Checkpoint Therapeutics \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Public Offering","leadProduct":"Cosibelimab","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Checkpoint Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Checkpoint Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Checkpoint Therapeutics \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Cosibelimab","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Checkpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Checkpoint Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Checkpoint Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Public Offering","leadProduct":"Cosibelimab","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Checkpoint Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"Checkpoint Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Checkpoint Therapeutics \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Public Offering","leadProduct":"Cosibelimab","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Checkpoint Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"Checkpoint Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Checkpoint Therapeutics \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Public Offering","leadProduct":"Cosibelimab","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Checkpoint Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"Checkpoint Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Checkpoint Therapeutics \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Cosibelimab","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Checkpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Checkpoint Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Checkpoint Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Cosibelimab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Checkpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Checkpoint Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Checkpoint Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Cosibelimab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Checkpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Checkpoint Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Checkpoint Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Cosibelimab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Checkpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Checkpoint Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Checkpoint Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Cosibelimab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Checkpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Checkpoint Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Checkpoint Therapeutics \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Checkpoint Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
filter

Year

filter

DEALS // DEV.

filter

Country

filter
Sponsor
filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

Therapeutic Area by Lead Product

ForexGraph

Study Phase by Lead Product

ForexGraph

Company by Lead Product

ForexGraph

Top Deals by Deal Size (USD bn)

ForexGraph

01

PharmScience R&D
Not Confirmed
PharmScience R&D
Not Confirmed

Details : Unloxcyt (cosibelimab) is a fully-human PD-L1 inhibitor antibody, approved for the treatment of patiens with cutaneous squamous cell carcinoma.

Product Name : Undisclosed

Product Type : Large molecule

Upfront Cash : Not Applicable

December 13, 2024

Lead Product(s) : Cosibelimab,Cisplatin,Carboplatin

Therapeutic Area : Oncology

Highest Development Status : Approved

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

02

PharmScience R&D
Not Confirmed
PharmScience R&D
Not Confirmed

Details : CK-301 (cosibelimab) is a fully-human PD-L1 inhibitor antibody, whch is currently being evaluated for the treatment of patiens with cutaneous squamous cell carcinoma.

Product Name : CK-301

Product Type : Large molecule

Upfront Cash : Not Applicable

July 25, 2024

Lead Product(s) : Cosibelimab

Therapeutic Area : Oncology

Highest Development Status : Phase III

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

03

PharmScience R&D
Not Confirmed
PharmScience R&D
Not Confirmed

Details : CK-301 (cosibelimab) is a fully-human mAb of IgG1 subtype that directly binds to PD-L1 and blocks the PDL1 interaction. It is being evaluated for cutaneous squamous cell carcinoma.

Product Name : CK-301

Product Type : Large molecule

Upfront Cash : Not Applicable

July 02, 2024

Lead Product(s) : Cosibelimab

Therapeutic Area : Oncology

Highest Development Status : Phase III

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

04

PharmScience R&D
Not Confirmed
PharmScience R&D
Not Confirmed

Details : CK-301 (cosibelimab) is a potential anti-PD-L1 antibody, which will be a new treatment for patients with selected recurrent or metastatic cancers, including metastatic and locally advanced cSCC.

Product Name : CK-301

Product Type : Large molecule

Upfront Cash : Not Applicable

June 24, 2024

Lead Product(s) : Cosibelimab

Therapeutic Area : Oncology

Highest Development Status : Phase III

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

05

PharmScience R&D
Not Confirmed
PharmScience R&D
Not Confirmed

Details : The net proceeds will be used to develop CK-301 (cosibelimab), an anti-programmed death-ligand for treating selected recurrent or metastatic cancers, including cutaneous squamous cell carcinoma.

Product Name : CK-301

Product Type : Large molecule

Upfront Cash : Undisclosed

January 29, 2024

Lead Product(s) : Cosibelimab

Therapeutic Area : Oncology

Highest Development Status : Phase III

Sponsor : H.C. Wainwright & Co.

Deal Size : $14.0 million

Deal Type : Public Offering

blank

06

PharmScience R&D
Not Confirmed
PharmScience R&D
Not Confirmed

Details : CK-301 (cosibelimab) is a fully-human mAb of IgG1 subtype that directly binds to PD-L1 and blocks the PDL1 interaction with the PD-1 and B7.1 receptors. It is under phase 3 clinical development for the treatment of cutaneous squamous cell carcinoma.

Product Name : CK-301

Product Type : Large molecule

Upfront Cash : Not Applicable

December 18, 2023

Lead Product(s) : Cosibelimab

Therapeutic Area : Oncology

Highest Development Status : Phase III

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

07

PharmScience R&D
Not Confirmed
PharmScience R&D
Not Confirmed

Details : Checkpoint intends to use the proceeds for the manufacturing of CK-301 (cosibelimab), a potential best-in-class anti-PD-L1 antibody being developed in patients with selected recurrent or metastatic cancers.

Product Name : CK-301

Product Type : Large molecule

Upfront Cash : Undisclosed

October 02, 2023

Lead Product(s) : Cosibelimab

Therapeutic Area : Oncology

Highest Development Status : Phase III

Sponsor : H.C. Wainwright & Co.

Deal Size : $11.1 million

Deal Type : Public Offering

blank

08

PharmScience R&D
Not Confirmed
PharmScience R&D
Not Confirmed

Details : Checkpoint intends to use the net proceeds for the manufacturing of CK-301 (cosibelimab), a potential best-in-class anti-PD-L1 antibody, being developed for advanced cutaneous squamous cell carcinoma.

Product Name : CK-301

Product Type : Large molecule

Upfront Cash : Undisclosed

July 31, 2023

Lead Product(s) : Cosibelimab,Cisplatin,Pemetrexed

Therapeutic Area : Oncology

Highest Development Status : Phase III

Sponsor : H.C. Wainwright & Co.

Deal Size : $10.0 million

Deal Type : Public Offering

blank

09

PharmScience R&D
Not Confirmed
PharmScience R&D
Not Confirmed

Details : CK-301 (cosibelimab) is a fully-human mAb of IgG1 subtype that directly binds to PD-L1 and blocks the PDL1 interaction with the PD-1 and B7.1 receptors, which removes the suppressive effects of PD-L1 on anti-tumor CD8+ T-cells to restore the cytotoxic T ...

Product Name : CK-301

Product Type : Large molecule

Upfront Cash : Not Applicable

July 27, 2023

Lead Product(s) : Cosibelimab

Therapeutic Area : Oncology

Highest Development Status : Phase III

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

10

PharmScience R&D
Not Confirmed
PharmScience R&D
Not Confirmed

Details : Checkpoint intends to use the net proceeds for the manufacturing of CK-301 (cosibelimab), a fully human monoclonal antibody of IgG1 subtype that directly binds to PD-L1 and certain pre-commercial activities in anticipation of potential approval and comme...

Product Name : CK-301

Product Type : Large molecule

Upfront Cash : Undisclosed

May 23, 2023

Lead Product(s) : Cosibelimab,Pemetrexed,Cisplatin

Therapeutic Area : Oncology

Highest Development Status : Phase III

Sponsor : H.C. Wainwright & Co.

Deal Size : $10.0 million

Deal Type : Public Offering

blank